Table 2.

Association of methylation level of the NT5E gene with clinicopathologic characteristics.

Clinicopathologic Characteristics		NT5E Gene Methylation
		Mean Levels (%)	p-Value
Age (years)	<50	39.4 ± 17.88	0.312
	≥50	33.63 ± 19.58
Menopausal state	Pre-menopausal	43.00 ± 19.73	0.031 *
	Post-menopausal	30.79 ± 16.31
Stage	I	31.77 ± 3.55	0.4
	II	36.83 ± 21.02
	III	36.76 ± 21.10
	IV	59.53 ± 13.89
Tumor size (cm)	≤2	30.53 ± 16.60	0.024 *
	>2	43.03 ± 19.97
Nodal involvement	Negative	35.10 ± 17.82	0.735
	Positive	37.06 ± 21.16
Distant metastasis	Negative	34.80 ± 18.57	0.071
	Positive	59.53 ± 13.88
Histologic grade	I	23.42 ± 8.15	0.01 *
	II	28.62 ± 15.75
	III	42.75 ± 19.81
Lymphovascular Invasion	Negative	36.60 ± 16.06	0.758
	Positive	34.85 ± 22.71
ER status	Negative	46.09 ± 17.97	0.01 *
	Positive	31.06 ± 17.70
PR status	Negative	44.25 ± 16.45	0.116
	Positive	33.58 ± 19.16
HER2 overexpression	Negative	36.18 ± 21.42	0.909
	Positive	36.90 ± 17.17
Bcl-2	Negative	53.71 ± 19.98	0.002 *
	Positive	32.19 ± 16.76
Molecular subtype	Luminal A	24.01 ± 13.45	0.099
	Luminal B	38.59 ± 20.56
	HER2	47.08 ± 18.21
	Basal-like	36.75 ± 16.29

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; Bcl-2, B-cell lymphoma 2. * Indicates statistically significant (p < 0.05).